Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML)

Trial ID or NCT#

NCT00890929

Status

not recruiting iconNOT RECRUITING

Purpose

This study has a phase 1 and a phase 2 component. In phase 1, the objective is to determine the maximum tolerated dose (MTD) of lenalidomide when after azacitidine. In phase 2, the objective is to determine the efficacy of the combination treatment.

Official Title

A Phase 1-2 Study of Azacitidine in Combination With Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia

Eligibility Criteria

Ages Eligible for Study: Older than 60 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Jason Gotlib
Hematologist-Oncologist
Professor of Medicine (Hematology)

Contact us to find out if this trial is right for you.

Contact

Leonel Gallegos
6507232781

View on ClinicalTrials.gov